Nuvalent, Inc.
NUVLNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$414.3M | −$280.4M | −$149.5M | −$86.1M | −$45.8M | −$16.9M |
| Net income | −$425.4M | −$260.8M | −$126.2M | −$81.9M | −$46.3M | −$14.6M |
| Total assets | $1.41B | $1.14B | $732.4M | $482.5M | $293.8M | $10.6M |
| Total liabilities | $164.4M | $72.0M | $31.8M | $19.5M | $8.8M | $6.6M |
| Equity | $1.25B | $1.07B | $700.6M | $463.0M | $285.0M | −$31.3M |
| EPS (diluted) | $-5.85 | $-3.93 | $-2.17 | $-1.65 | $-2.13 | $-5.08 |
| Shares out. | 72.7M | 66.4M | 58.2M | 49.7M | 21.8M | 2.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −34.1%
- Return on assets
- −30.1%
- Return on capital (ROCE)
- −31.4%
- Liabilities / assets
- 11.6%
- Debt / equity
- 0.13×
- Book value / share
- $17.17
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 9.80safe
- Accruals / assets
- −10.6%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2027-01A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Phase 1/2Recruitingreadout ~2027-12A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2Recruitingreadout ~2027-12-31A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Phase 3Recruitingreadout ~2029-12Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Flynn James EPassive (13G)Feb 12, 2026
- Blackrock, Inc.Passive (13G)Jul 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.9M | 9.5 | -3.1% |
| Apr 30, 2026 | 5.1M | 8.3 | +10.3% |
| Apr 15, 2026 | 4.6M | 7.8 | -7.8% |
| Mar 31, 2026 | 5.0M | 8.5 | -12.6% |
| Mar 13, 2026 | 5.7M | 10.8 | +2.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Other material eventApr 7, 2026
- Results of operationsFeb 26, 2026
- Results of operationsJan 14, 2026
- Other material eventDec 16, 2025
- Director / officer changeDec 10, 2025
- Entered a material agreement · Other material eventNov 20, 2025
- Other material eventNov 17, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.